Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.

被引：0
|
作者：
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Wang, Jiuzhou
Esteves, Brooke
Zweidler-McKay, Patrick A.
Moore, Kathleen N.
O'Malley, David M.
机构：
[1] McGill Univ, Royal Victoria Hosp, Hlth Ctr, Montreal, PQ, Canada
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[5] Renown Reg Med Ctr, Ctr Hope, Reno, NE USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Reading, MA USA
[7] Univ Montreal, Montreal, PQ, Canada
[8] Univ Calif Los Angeles, Los Angeles, CA USA
[9] ImmunoGen Inc, Waltham, MA USA
[10] Kadmon Rsrch Inst, Wilmington, MA USA
[11] ImmunoGen, Waltham, MA USA
[12] Univ Oklahoma, Med Ctr, Oklahoma City, OK USA
[13] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6004
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
    Zhu, Youwen
    Lin, Yinxin
    Liu, Kun
    Zhu, Hong
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
  • [42] A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
    Trillsch, Fabian
    Schochter, Fabienne
    Park-Simon, Tjoung-Won
    Reuss, Alexander
    Fehm, Tanja N.
    Wimberger, Pauline
    Bronger, Holger
    Schmalfeldt, Barbara
    Sehouli, Jalid
    Marme, Frederik
    Heitz, Florian
    Mahner, Sven
    Fredrich, Michaela
    Barth, Stefanie
    Stec, James Joseph
    Method, Michael W.
    Harter, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Antibody-drug conjugate targeting folate receptor α: a new milestone in personalized medicine for high-grade serous ovarian cancer
    Gonzalez-Martin, Antonio
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (08) : 1126 - 1127
  • [44] Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial
    Coleman, Robert L.
    Lorusso, Domenica
    Oaknin, Ana
    Cecere, Sabrina Chiara
    Denys, Hannelore
    Colombo, Nicoletta
    van Gorp, Toon
    Konner, Jason A.
    Marin, Margarita Romeo
    Harter, Philipp
    Murphy, Conleth
    Wang, Yuemei
    Esteves, Brooke
    Method, Michael
    Matulonis, Ursula
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (08) : 1119 - 1125
  • [45] STRATEGIES FOR COLLABORATIVE MANAGEMENT OF OCULAR ADVERSE EVENTS OF ELAHERET (MIRVETUXIMAB SORAVTANSINE) IN PATIENTS WITH FOLATE RECEPTOR ALPHA (FRa)-POSITIVE RECURRENT OVARIAN CANCER
    Arn, Courtney
    Riaz, Kamran
    Hendershot, Andrew
    Moore, Kathleen
    O'Malley, David
    Lyle, Kathryn
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [46] IMGN853, a folate receptor (FR) a-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression
    Ab, Olga
    Bartle, Laura M.
    Sun, Xiuxia
    Wu, Rui
    Johnson, Holly A.
    Whiteman, Kathleen R.
    LaBelle, Alyssa
    Goldmacher, Victor S.
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Preclinical evaluation of M-DGN549, a folate receptor alpha-targeting antibody-drug conjugate (ADC) with a DNA-alkylating payload
    Setiady, Y.
    Lanieri, L.
    Ab, O.
    Maloney, E.
    Hong, E.
    Qiu, Q.
    Zhou, Y.
    Zhao, J.
    Themeles, M.
    Zhang, X.
    Pinkas, J.
    Soto, R. Ruiz
    Ponte, J.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S145 - S145
  • [48] PHASE 1 DOSE-ESCALATION STUDY OF STRO-002, AN ANTI-FOLATE RECEPTOR ALPHA (FRα) ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED PLATINUM-RESISTANT/REFRACTORY EPITHELIAL OVARIAN CANCER (OC)
    Naumann, R.
    Braiteh, F.
    Diaz, J.
    Hamilton, E.
    Diab, S.
    Schilder, R.
    Moroney, J.
    Martin, L.
    Uyar, D.
    O'Malley, D.
    Penson, R.
    DiLea, C.
    Palumbo, M.
    DeAlmeida, V.
    Berman, C.
    Matheny, S.
    Molina, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A61 - A61
  • [49] Initial results from a first-in-human study of AZD5335, a folate receptor a (FRa)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)
    Shapira-Frommer, R.
    Sudo, K.
    Harano, K.
    Mileshkin, L.
    Perets, R.
    Song, M.
    Cohen, J.
    Huang, Y-F.
    Ambrose, H.
    Brier, T.
    Dosani, A.
    Fraenkel, P. G.
    Kmieciak, A.
    Mitchell, P.
    Myers, C.
    Wang, J.
    Odegbami, R. I.
    Sykes, A.
    Turner, S.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S572 - S573
  • [50] IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors
    Ab, Olga
    Whiteman, Kathleen R.
    Bartle, Laura M.
    Sun, Xiuxia
    Singh, Rajeeva
    Tavares, Daniel
    LaBelle, Alyssa
    Payne, Gillian
    Lutz, Robert J.
    Pinkas, Jan
    Goldmacher, Victor S.
    Chittenden, Thomas
    Lambert, John M.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07) : 1605 - 1613
12345